AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. | ...

The primary endpoint was functional immune tolerance, defined as off all immunosuppressive drugs 24 months after ...

Explore how AI transforms cardiac amyloidosis detection with remarkable accuracy—keep reading to see its clinical potential.

A multidisciplinary guideline panel convened by the American Association of Bronchology and Interventional Pulmonology (AABIP ...

Techcyte is proud to share results from a published pilot study demonstrating the effectiveness of its AI-powered kidney ...